Latest news with #Genus
Yahoo
28-05-2025
- Business
- Yahoo
Exploring Three High Growth Tech Stocks in the United Kingdom
The UK market has recently experienced some turbulence, with the FTSE 100 index closing lower due to weak trade data from China, highlighting global economic challenges and affecting companies tied to Chinese fortunes. In this environment, identifying high growth tech stocks in the United Kingdom involves looking for companies that demonstrate resilience and innovation despite broader market pressures, offering potential opportunities for growth even when traditional sectors face headwinds. Name Revenue Growth Earnings Growth Growth Rating Audioboom Group 8.84% 59.33% ★★★★★☆ YouGov 4.12% 64.42% ★★★★★☆ Redcentric 5.32% 67.90% ★★★★★☆ Oxford Biomedica 16.80% 80.47% ★★★★★☆ Windar Photonics 37.17% 46.73% ★★★★★☆ Quantum Base Holdings 132.55% 92.87% ★★★★★☆ Trustpilot Group 15.02% 40.20% ★★★★★☆ Faron Pharmaceuticals Oy 55.41% 56.79% ★★★★★☆ Vinanz 113.60% 125.86% ★★★★★☆ Cordel Group 33.50% 148.58% ★★★★★☆ Click here to see the full list of 41 stocks from our UK High Growth Tech and AI Stocks screener. We'll examine a selection from our screener results. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Genus plc is an animal genetics company with operations across North America, Latin America, the United Kingdom, Europe, the Middle East, Russia, Africa, and Asia and has a market cap of approximately £1.35 billion. Operations: Genus plc generates revenue primarily from its two main segments: Genus ABS, which accounts for £311.10 million, and Genus PIC, contributing £358 million. The company operates globally across various regions including North America, Latin America, and Asia. Genus, while not currently profitable, is poised for significant transitions with expected earnings growth of 46.67% annually and revenue increases at 3.9% per year, outpacing the UK market's 3.7%. The recent FDA approval for its PRP gene edit marks a pivotal advancement in the U.S. food supply chain, potentially boosting future revenues as commercialization progresses in key international markets. Additionally, the strategic appointment of Andy Russell as CFO could enhance financial strategies ahead of its profitability forecast within three years, aligning with Genus's growth trajectory in biotechnology amidst challenging industry comparisons due to current unprofitability. Navigate through the intricacies of Genus with our comprehensive health report here. Explore historical data to track Genus' performance over time in our Past section. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Kainos Group plc provides digital technology services across the United Kingdom, Ireland, North America, Central Europe, and internationally with a market capitalization of £898.57 million. Operations: Kainos Group focuses on delivering digital technology services, generating revenue primarily from its operations in the UK, Ireland, North America, and Central Europe. The company emphasizes a streamlined cost structure to enhance operational efficiency. Kainos Group, a UK-based tech firm, demonstrates resilience with its strategic share repurchase program, having recently completed a buyback of 3.993 million shares for £30 million. While the company's revenue dipped to £367.25 million from £382.39 million year-over-year, its commitment to shareholder value is evident in the proposed dividend of 19.1 pence per share and an aggressive earnings forecast projecting growth at 16.9% annually—outpacing the UK market average of 14.5%. These initiatives reflect Kainos's adaptability in a fluctuating tech landscape and its potential to sustain growth amidst challenging conditions. Get an in-depth perspective on Kainos Group's performance by reading our health report here. Examine Kainos Group's past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★☆ Overview: Trustpilot Group plc operates an online review platform connecting businesses and consumers globally, with a market cap of £976.83 million. Operations: The company generates revenue of $210.75 million through its online review platform, primarily serving as an Internet Information Provider across the United Kingdom, North America, Europe, and other international markets. With a robust 15% annual revenue growth and an impressive 40.2% forecast in earnings growth, Trustpilot Group stands out in the UK tech sector. The company's recent introduction of innovative features that leverage customer feedback to enhance business strategies highlights its commitment to integrating cutting-edge technology with user experience. These developments not only aim to boost conversion rates but also solidify customer loyalty, underpinning Trustpilot's strategy to transform trust into tangible business outcomes. At its recent AGM, the focus on expanding directorial oversight and refining audit processes further underscores its strategic intent to fortify governance and drive sustained growth. Click here and access our complete health analysis report to understand the dynamics of Trustpilot Group. Understand Trustpilot Group's track record by examining our Past report. Embark on your investment journey to our 41 UK High Growth Tech and AI Stocks selection here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LSE:GNS LSE:KNOS and LSE:TRST. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
26-05-2025
- Business
- Yahoo
Institutional investors in Genus plc (LON:GNS) lost 3.3% last week but have reaped the benefits of longer-term growth
Given the large stake in the stock by institutions, Genus' stock price might be vulnerable to their trading decisions A total of 10 investors have a majority stake in the company with 51% ownership Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. A look at the shareholders of Genus plc (LON:GNS) can tell us which group is most powerful. With 81% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). No shareholder likes losing money on their investments, especially institutional investors who saw their holdings drop 3.3% in value last week. However, the 12% one-year returns may have helped alleviate their overall losses. We would assume however, that they would be on the lookout for weakness in the future. Let's take a closer look to see what the different types of shareholders can tell us about Genus. See our latest analysis for Genus Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that Genus does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Genus' historic earnings and revenue below, but keep in mind there's always more to the story. Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It looks like hedge funds own 6.7% of Genus shares. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Wellington Management Group LLP is currently the largest shareholder, with 9.8% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 7.1% and 6.7%, of the shares outstanding, respectively. We did some more digging and found that 10 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our data suggests that insiders own under 1% of Genus plc in their own names. Keep in mind that it's a big company, and the insiders own UK£3.6m worth of shares. The absolute value might be more important than the proportional share. Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling. The general public, who are usually individual investors, hold a 11% stake in Genus. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. It's always worth thinking about the different groups who own shares in a company. But to understand Genus better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Genus . If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
07-05-2025
- Health
- Yahoo
FDA Approves Gene-Hacked CRISPR Pigs for Human Consumption
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Generate Key Takeaways The US Food and Drug Administration has approved a type of CRISPR gene-edited pig for human consumption. As MIT Technology Review reports, only an extremely limited list of gene-modified animals are cleared by regulators to be eaten in the United States, including a transgenic salmon that has an extra gene to grow faster, and heat-tolerant beef cattle. And now a type of illness-resistant pig could soon join their ranks. British company Genus used the popular gene-editing technique CRISPR to make pigs immune to a virus that causes an illness called porcine reproductive and respiratory syndrome (PRRS). It's the same technology that's been used to gene-hack human babies — experiments that have proven far more controversial — and develop medicine in the form of gene therapies. The PRRS virus can easily spread in factory farms in the US and cause the inability to conceive, increase the number of stillborn pigs, and trigger respiratory complications, including pneumonia. It's been called the "most economically important disease" affecting pig producers, since it can have a devastating effect on their bottom lines. According to MIT Tech, it causes losses of more than $300 million a year in the US alone. Genus' gene-editing efforts have proven highly successful so far, with the pigs appearing immune to 99 percent of known versions of the virus. Using CRISPR, the company knocked out a receptor that allowed the PRRS virus to enter cells, effectively barring it from infecting its host. Beyond the respiratory illness, scientists are using gene-editing to make pigs less vulnerable or even immune to other infections, including swine fever. But before we can eat a pork chop from a gene-edited pig, Genus says that it will have to lock down regulatory approval in Mexico, Canada, Japan, and China as well, the United States' biggest export markets for pork, as MIT Tech reports. The company is hoping gene-edited pork could land in the US market as soon as next year. But whether you'll actually know if you're eating meat from a pig that had a virus receptor turned off using a cutting-edge DNA modification technique is unclear. "We aren't aware of any labelling requirement," Genus subsidiary Pig Improvement Company CEO Matt Culbertson told MIT Tech. More on CRISPR: Scientist Who Gene-Hacked Human Babies Says Ethics Are "Holding Back" Scientific Progress
Hindustan Times
07-05-2025
- Business
- Hindustan Times
Amazon Great Summer Sale Ends Tomorrow! Save BIG on the best inverter batteries with up to 50% off on top brands
Amazon's Great Summer Sale ends tomorrow, offering up to 50% off on top inverter battery brands like Luminous, Genus, Livguard, and OKAYA. Perfect for handling summer power cuts, these batteries provide reliable home backup with advanced features at discounted prices.
Telegraph
06-05-2025
- Business
- Telegraph
Founded in an Oxfordshire pub, this business leads the world in pig polishing
Questor is The Telegraph's stock-picking column, helping you decode the markets and offering insights on where to invest. Confusion still reigns as Donald Trump strikes a trade deal with Ukraine and offers further exemptions to his proposed package of reciprocal tariffs, but continues to posit income tax cuts funded by revenues generated from these very duties. The first two are helping to drive double-digit percentage rallies from early April's lows in headline US equity indices such as the S&P 500 and the Nasdaq and healthy gains elsewhere, including the UK. Whether the bottom is in, or whether this is a classic short-covering, bear-market rally is hard to gauge because nobody knows what is coming next. Those investors who seek a haven from the volatility can perhaps seek out defensive sectors and companies, where demand is relatively insulated from the vagaries of the economic cycle, such as utilities. Portfolio holdings such as National Grid and SSE fit the bill here. Another approach is to look for firms where the business model has a distinct rhythm of its own, which brings us to animal genetics specialist Genus. The business has two main units – pig improvement company (PIC) and American breeders service (ABS) – which serve the porcine and bovine markets respectively, across the globe. Genus's analysis and expertise in genomics helps farmers to raise animals which grow faster and are more resistant to disease, to help meet the growing demand for protein while reducing resource needs and environmental impact. In the case of ABS, Genus can help dairy farmers increase the chance of cows giving birth to female calves suitable for dairy production or young more suited to beef production. At PIC, revenues are recognised either upfront, in the form of full fair value for the animal, or via royalties as piglets are weaned, while ABS sells straws of semen or embryos from elite genetic lines, as well as related technical services. PIC is the global leader in its field while ABS ranks second in the bovine arena. Besides this strong competitive position, there are three potential reasons for looking more closely at the Basingstoke-headquartered company. First, the share price chart goes from the top-left-hand corner of the screen to the bottom right for most of the past five years, something that always catches this column's eye. The shares are down by 70pc from their 2021 highs, largely thanks to the conclusion of pig herd restocking in China in the wake of a swine fever outbreak and a subsequent collapse in pork prices there. Second, the company's first-half results in January delivered what analysts described as the first positive upside surprise to earnings estimates for three years, suggesting the company had finally turned a corner. Finally, America's key regulator in this area, the Food and Drug Administration (FDA) is giving its approval to Genus's porcine reproductive and respiratory syndrome (PRRS) pig resistant programme (PRP). Brazil had already given PRP and gene-edited pigs the nod, and other nations, such as Mexico, Canada and Japan, may now be inclined to do the same. Given the devastating effect the PRRS virus can have upon herds – and farmers' incomes owing to the antibiotics bills and premature death rates – demand could be strong, to the great benefit of Genus' sales and profits. FDA approval opens the way to commercialisation of PRP and analysts' forecasts are yet to really factor in the potential upside. As ever, there are risks. The US represents nearly 40pc of Genus's total sales, primarily from the PIC. As a result, Trump, trade and tariffs again hover into view. The good news is that Genus imports little and it has five sites in America, including a research and development team in Madison, Wisconsin. The danger comes from Genus exports from America, should other nations impose retaliatory tariffs, especially Mexico and Canada, so investors must keep a watching brief here. In addition, net debt has climbed in the past few years, thanks in part to new leases on farms in China, while the valuation does not look that tempting at first glance. In the case of the former, at least interest cover is still good, once a number of exceptional items are taken out of fiscal 2024's messy set of results. With regard to the latter, earnings are still relatively depressed, so that inflates the price-to-earnings multiple, and the rating could start to drop quickly if PRP delivers on its potential and profits growth gathers fresh momentum. Europe's outbreak of foot-and-mouth disease is another near-term complication, although a severe episode could eventually force farmers to restock in the manner of China at the turn of this decade, a process which gave Genus's profits and cash flows a lift. Questor says: Buy Ticker: GNS
